Nothing Special   »   [go: up one dir, main page]

PE20100362A1 - Derivados de purina que expanden las celulas madre hematopoyeticas - Google Patents

Derivados de purina que expanden las celulas madre hematopoyeticas

Info

Publication number
PE20100362A1
PE20100362A1 PE2009001206A PE2009001206A PE20100362A1 PE 20100362 A1 PE20100362 A1 PE 20100362A1 PE 2009001206 A PE2009001206 A PE 2009001206A PE 2009001206 A PE2009001206 A PE 2009001206A PE 20100362 A1 PE20100362 A1 PE 20100362A1
Authority
PE
Peru
Prior art keywords
expand
purin
benzo
phenol
ethyl
Prior art date
Application number
PE2009001206A
Other languages
English (en)
Inventor
Anthony E Boitano
Michael Cooke
Shifeng Pan
Peter G Schultz
John TELLEW
Yongqin Wan
Xing Wang
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of PE20100362A1 publication Critical patent/PE20100362A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN DERIVADO HETEROCICLICO DE FORMULA (I), DONDE G1 ES N O CR3; R3 ES H, ALQUILO C1-C4 O BIFENILO; G2, G3 Y G4 SON CH O N, CON LA CONDICION DE QUE AL MENOS UNO DE G3 Y G4 ES N, Y G1 Y G2 NO SON AMBOS N; L ES NR5aCH(C(O)OCH3)CH2-, NR5a(CH2)2S-, NR5aCH2CH(CH3)CH2, ENTRE OTROS; R5a ES H O ALQUILO C1-C4; R1 ES H, FENILO, FURANILO, ENTRE OTROS; R2 ES FENILO, PIRIDINILO, INDOLILO, ENTRE OTROS; R4 ES ALQUILO C1-C10, CICLOHEXILO, CICLOPROPILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(2-(2-(BENZO-[b]-TIOFEN-3-IL)-9-ISOPROPIL-9H-PURIN-6-IL-AMINO)-ETIL)-FENOL, 4-(2-(2-(BENZO-[b]-TIOFEN-3-IL)-9-SEC-BUTIL-9H-PURIN-6-IL-AMINO)-ETIL)-FENOL, 4-(2-(9-(BENZIDRIL-2-(BENZO-[b]-TIOFEN-3-IL)-9H-PURIN-6-IL-AMINO)-ETIL)-FENOL, ENTRE OTROS. TAMBIEN ESTA REFERIDA A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS TIENEN ACTIVIDAD SUB-REGULADORA DE LA ACTIVIDAD DEL RECEPTOR DE HIDROCARBURO DE ARILO PARA EXPANDIR EL NUMERO DE CELULAS CD34+ Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS HEMATOPOYETICOS TALES COMO LEUCEMIA MIELOIDE AGUDA, LEUCEMIA LINFOBLASTICA AGUDA, ENFERMEDAD DE HODKING, ENTRE OTRAS
PE2009001206A 2008-10-30 2009-10-27 Derivados de purina que expanden las celulas madre hematopoyeticas PE20100362A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10982108P 2008-10-30 2008-10-30
US24276509P 2009-09-15 2009-09-15

Publications (1)

Publication Number Publication Date
PE20100362A1 true PE20100362A1 (es) 2010-05-27

Family

ID=42111339

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001206A PE20100362A1 (es) 2008-10-30 2009-10-27 Derivados de purina que expanden las celulas madre hematopoyeticas

Country Status (41)

Country Link
US (4) US8927281B2 (es)
EP (2) EP2350078B1 (es)
JP (1) JP5390626B2 (es)
KR (1) KR101434719B1 (es)
CN (1) CN102203096B (es)
AR (1) AR074063A1 (es)
AU (1) AU2009317898B2 (es)
BR (1) BRPI0921799B8 (es)
CA (3) CA2740589C (es)
CL (2) CL2009002010A1 (es)
CO (1) CO6410309A2 (es)
CR (1) CR20110192A (es)
CU (1) CU24495B1 (es)
CY (1) CY1121857T1 (es)
DK (1) DK2350078T3 (es)
DO (1) DOP2011000114A (es)
EA (1) EA019872B1 (es)
EC (1) ECSP11011090A (es)
ES (2) ES2736728T3 (es)
GE (1) GEP20146053B (es)
HN (1) HN2011001195A (es)
HR (1) HRP20191238T1 (es)
HU (1) HUE044802T2 (es)
IL (1) IL212368A (es)
JO (1) JO3593B1 (es)
LT (1) LT2350078T (es)
MA (1) MA32828B1 (es)
MX (1) MX347834B (es)
MY (1) MY155137A (es)
NI (1) NI201100083A (es)
NZ (1) NZ592435A (es)
PE (1) PE20100362A1 (es)
PL (1) PL2350078T3 (es)
PT (1) PT2350078T (es)
RS (1) RS59027B1 (es)
SI (1) SI2350078T1 (es)
SM (1) SMP201100024B (es)
SV (1) SV2011003888A (es)
TN (1) TN2011000174A1 (es)
TW (1) TWI532486B (es)
WO (1) WO2010059401A2 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
NZ579248A (en) * 2007-03-28 2011-08-26 Neurosearch As Purinyl derivatives and their use as potassium channel modulators
EP2142545A1 (en) * 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
EP2279188B1 (en) * 2008-05-30 2015-01-28 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
US8268838B2 (en) * 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
EP2344501A1 (en) * 2008-09-26 2011-07-20 NeuroSearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9212348B2 (en) 2010-12-01 2015-12-15 Nissan Chemical Industries, Ltd. Method for producing hematopoietic stem cells using pyrazole compounds
WO2012102937A2 (en) * 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
US9353115B2 (en) 2011-06-01 2016-05-31 Janus Biotherapeutics, Inc. Immune system modulators
JP2014523741A (ja) * 2011-07-06 2014-09-18 セレラント セラピューティクス インコーポレイテッド 血小板産生のための巨核球前駆細胞
EP2739735A2 (en) * 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US9593062B2 (en) * 2011-09-07 2017-03-14 Deutschland Krebsforschungszentrum Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
AU2012347534B2 (en) * 2011-12-08 2018-01-25 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
ES2733946T3 (es) 2012-01-27 2019-12-03 Univ Montreal Derivados de pirimido[4,5-b]indol y su uso en la expansión de células madre hematopoyéticas
EP2814950A1 (en) 2012-02-13 2014-12-24 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
MX2014014872A (es) 2012-06-26 2015-08-06 Saniona Aps Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
US9567569B2 (en) * 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9074186B2 (en) * 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
EP2943566A1 (en) 2013-01-08 2015-11-18 Fred Hutchinson Cancer Research Center Compositions and methods for expansion of embryonic hematopoietic stem cells
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
US9757378B2 (en) * 2013-05-17 2017-09-12 Universite De Montreal Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation
SG11201603166UA (en) * 2013-10-24 2016-05-30 Ospedale San Raffaele Srl Method
SG10201803533YA (en) 2013-10-31 2018-06-28 Hutchinson Fred Cancer Res Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
EP3995142A3 (en) 2015-04-29 2022-08-24 Fred Hutchinson Cancer Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
SG10201912576PA (en) * 2015-10-15 2020-02-27 Celularity Inc Natural killer cells and ilc3 cells and uses thereof
CA3001137A1 (en) 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
EP3368660A4 (en) 2015-10-30 2019-04-24 The Regents Of The University Of California METHOD FOR GENERATING T-CELLS FROM STEM CELLS AND IMMUNOTHERAPEUTIC PROCEDURES USING T-CELLS
EP3397767A1 (en) * 2015-12-28 2018-11-07 Novartis AG Compositions and methods for the treatment of hemoglobinopathies
CA3020857A1 (en) 2016-04-14 2017-10-19 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
MX2018013565A (es) * 2016-05-07 2019-08-21 Celularity Inc Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales.
PE20190509A1 (es) 2016-05-25 2019-04-10 Bayer Pharma AG 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
EP3500562B1 (en) * 2016-08-18 2023-11-15 National University of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
EP3519577A1 (en) 2016-09-28 2019-08-07 Novartis AG Porous membrane-based macromolecule delivery system
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
AU2018253115B2 (en) * 2017-04-12 2022-08-11 Edigene Biotechnology, Inc. Aryl hydrocarbon receptor antagonists and uses thereof
MX2019012431A (es) * 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
SG11201909571SA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
CN110958879A (zh) 2017-07-31 2020-04-03 诺华股份有限公司 玛沃谷兰在减少可卡因使用或预防复用可卡因中的用途
CA3071534A1 (en) * 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
JP2020537541A (ja) 2017-09-29 2020-12-24 インテリア セラピューティクス，インコーポレーテッド 脂質ナノ粒子を用いるインビトロでのｍｒｎａの送達方法
CA3079405A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
CA3079404A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3713931A1 (en) 2017-11-21 2020-09-30 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11304946B2 (en) 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
CA3082858A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
WO2019101642A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
MX2020005878A (es) 2017-12-06 2020-10-07 Magenta Therapeutics Inc Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas.
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN111902411A (zh) * 2018-01-03 2020-11-06 美真达治疗公司 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法
US11530220B2 (en) 2018-02-06 2022-12-20 Ideaya Biosciences, Inc. Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
WO2020018848A1 (en) * 2018-07-19 2020-01-23 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
MX2021002215A (es) * 2018-08-24 2021-07-15 Jaguahr Therapeutics Pte Ltd Derivados de tetrahidropiridopirimidina como moduladores de ahr.
EP3843853A1 (en) 2018-08-31 2021-07-07 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
US11932657B2 (en) 2018-09-07 2024-03-19 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound
WO2020056170A1 (en) 2018-09-12 2020-03-19 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
BR112021007017A2 (pt) * 2018-10-16 2021-07-13 Ikena Oncology, Inc. inibidores de ahr de indol e usos dos mesmos
WO2020092694A2 (en) * 2018-10-31 2020-05-07 Magenta Therapeutics Inc. Methods for hematopoietic stem and progenitor cell transplant therapy
EP4013508A1 (en) * 2019-08-12 2022-06-22 Bayer Aktiengesellschaft [1,2,4]triazolo[1,5-c]quinazolin-5-amines
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11591339B2 (en) 2019-11-26 2023-02-28 Ikena Oncology, Inc. Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors
EP4073038A1 (en) 2019-12-09 2022-10-19 Otsuka Pharmaceutical Co., Ltd. Acrylamide compounds
JP2023506842A (ja) 2019-12-18 2023-02-20 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
WO2021173082A1 (en) 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
WO2021224416A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
CN115803435A (zh) 2020-05-06 2023-03-14 塞勒克提斯公司 用于在细胞基因组中靶向插入外源序列的方法
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022004864A1 (ja) 2020-07-01 2022-01-06 ネクスジェン株式会社 ヒト長期造血幹細胞マーカー
WO2022029063A1 (en) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
WO2022078356A1 (zh) * 2020-10-15 2022-04-21 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2023150393A2 (en) 2022-02-07 2023-08-10 Ensoma, Inc. Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399196A (en) 1959-01-22 1968-08-27 Ciba Geigy Corp Nu-substituted pyrazolo-pyrimidines
DE3150486A1 (de) * 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
US5437994A (en) 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5117830A (en) 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
FR2732604B1 (fr) * 1995-04-07 1997-06-06 Vacsyn Sa Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et compositions les contenant
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
DK1150982T3 (da) * 1999-02-01 2005-12-27 Cv Therapeutics Inc Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CN1110552C (zh) * 1999-07-13 2003-06-04 中国人民解放军第二军医大学 一种体外扩增造血干细胞的新方法
ATE315934T1 (de) 1999-09-10 2006-02-15 Smithkline Beecham Corp Thrombopoietin-mimetika
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
WO2001039773A1 (en) 1999-12-06 2001-06-07 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2004501062A (ja) 1999-12-17 2004-01-15 アライアッド・ファーマシューティカルズ・インコーポレーテッド 新規プリン類
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
CN1383380A (zh) * 2000-07-18 2002-12-04 尼基摩株式会社 干细胞增强材料
AU2002239718A1 (en) 2000-12-19 2002-07-01 Ligand Pharmaceuticals Thrombopoietin mimetics
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
US7176312B2 (en) * 2001-10-12 2007-02-13 The Scripps Research Institute Kinase inhibitor scaffolds and methods for their preparation
WO2003057241A1 (fr) * 2001-12-28 2003-07-17 Daiichi Suntory Pharma Co., Ltd. Agents favorisant la proliferation et/ou la differenciation de cellules souches hematopoietiques et/ou de precurseurs hematopoietiques
US7414040B2 (en) 2002-06-06 2008-08-19 Smithkline Beecham Corporation Thrombopoietin mimetics
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2004089068A (ja) * 2002-08-30 2004-03-25 Kobe University Ａｈ受容体リガンド特異的な遺伝子発現誘導因子及びその機能に基づく異種遺伝子誘導発現系の利用技術
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
WO2005026164A1 (en) * 2003-09-18 2005-03-24 Altana Pharma Ag Pharmacologically active imidazo[4,5-c]pyridines
MXPA06007095A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Conjugados de fosfonato inhibidores de cinasa.
JPWO2005080377A1 (ja) 2004-02-20 2007-10-25 キリンホールディングス株式会社 ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
EA200700543A1 (ru) * 2004-09-03 2007-10-26 Прометик Байосайенсиз Инк. Замещенные пуринилпроизводные с иммуномодулирующей и химиозащитной активностью и их применение как таковых или с жирными кислотами со средней длиной цепи или глицеридами
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR052771A1 (es) * 2004-09-30 2007-04-04 Tibotec Pharm Ltd Pirimidinas biciclicas inhibidoras del vhc
FR2876583B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
EP1824850A2 (en) * 2004-12-09 2007-08-29 Nycomed GmbH SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION
WO2006118914A2 (en) 2005-04-29 2006-11-09 Children's Medical Center Corporation Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition
PT1910338E (pt) 2005-07-14 2010-12-02 Irm Llc Compostos heterotetracíclicos como miméticos de tpo
CA2618634A1 (en) 2005-08-15 2007-02-22 Irm Llc Compounds and compositions as tpo mimetics
PE20080361A1 (es) * 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
JPWO2007145227A1 (ja) 2006-06-14 2009-11-05 中外製薬株式会社 造血幹細胞増加促進剤
WO2007149548A2 (en) * 2006-06-22 2007-12-27 Medistem Laboratories, Inc. Treatment of erectile dysfunction by stem cell therapy
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
WO2008028645A1 (en) 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
DK2076268T3 (da) 2006-10-19 2013-04-22 Genzyme Corp Roscovitin til behandling af visse cystiske sygdomme
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP2142545A1 (en) 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity

Also Published As

Publication number Publication date
TWI532486B (zh) 2016-05-11
EA201100663A1 (ru) 2011-12-30
RS59027B1 (sr) 2019-08-30
HUE044802T2 (hu) 2019-11-28
ES2736728T3 (es) 2020-01-07
CN102203096B (zh) 2014-09-17
US9580426B2 (en) 2017-02-28
ES2948567T3 (es) 2023-09-14
CL2013001874A1 (es) 2014-04-04
TN2011000174A1 (en) 2012-12-17
CO6410309A2 (es) 2012-03-30
MY155137A (en) 2015-09-15
WO2010059401A3 (en) 2010-09-23
PL2350078T3 (pl) 2019-09-30
SI2350078T1 (sl) 2019-08-30
CA2740589C (en) 2017-11-21
EA019872B1 (ru) 2014-06-30
CA2943540C (en) 2020-10-27
BRPI0921799B1 (pt) 2020-09-29
PT2350078T (pt) 2019-07-19
HRP20191238T1 (hr) 2019-11-29
US20170239296A1 (en) 2017-08-24
CR20110192A (es) 2011-06-10
SMAP201100024A (it) 2011-07-11
IL212368A0 (en) 2011-06-30
CA3061937A1 (en) 2010-05-27
GEP20146053B (en) 2014-03-10
KR20110075042A (ko) 2011-07-05
JP5390626B2 (ja) 2014-01-15
CU20110096A7 (es) 2012-01-31
EP3524604B1 (en) 2023-03-29
MA32828B1 (fr) 2011-11-01
CY1121857T1 (el) 2020-07-31
BRPI0921799B8 (pt) 2021-05-25
ECSP11011090A (es) 2011-09-30
CL2009002010A1 (es) 2010-06-25
NI201100083A (es) 2011-11-03
US20210187033A1 (en) 2021-06-24
CU24495B1 (es) 2021-01-12
JO3593B1 (ar) 2020-07-05
AU2009317898A1 (en) 2010-05-27
US20140114070A1 (en) 2014-04-24
US20100183564A1 (en) 2010-07-22
KR101434719B1 (ko) 2014-08-27
MX2011004593A (es) 2011-06-16
WO2010059401A2 (en) 2010-05-27
SMP201100024B (it) 2012-03-05
US8927281B2 (en) 2015-01-06
IL212368A (en) 2015-02-26
AR074063A1 (es) 2010-12-22
LT2350078T (lt) 2019-07-25
CN102203096A (zh) 2011-09-28
CA2943540A1 (en) 2010-05-27
DK2350078T3 (da) 2019-07-15
TW201028153A (en) 2010-08-01
EP2350078A2 (en) 2011-08-03
MX347834B (es) 2016-10-07
AU2009317898B2 (en) 2013-07-11
BRPI0921799A2 (pt) 2016-01-12
HN2011001195A (es) 2014-01-13
CA2740589A1 (en) 2010-05-27
JP2012507554A (ja) 2012-03-29
EP2350078B1 (en) 2019-04-17
DOP2011000114A (es) 2017-09-29
EP3524604A1 (en) 2019-08-14
NZ592435A (en) 2013-01-25
SV2011003888A (es) 2011-07-05

Similar Documents

Publication Publication Date Title
PE20100362A1 (es) Derivados de purina que expanden las celulas madre hematopoyeticas
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
ECSP10010209A (es) Agonistas novedosos de los receptores de glucocorticoides
PE20151375A1 (es) Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion
AR050694A1 (es) Dihidropteridinonas para el tratamiento de enfermedades oncologicas
HN2012001744A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
UY31612A1 (es) Derivados de incol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparación y su aplicación en terapéutica
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
CR11690A (es) Pirazolo (3,4-b) piridinas como inhibidores de raf
GT201200242A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CR20140197A (es) Compuestos con actividad nematicida
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
GT200800105A (es) Triazolopiridazinas como moduladores de tirosina cinasa
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
CU20110145A7 (es) Derivados de sulfonamida
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
NI201000231A (es) Inhibidores de ciclopropil polimerasa.
BR112015006454A2 (pt) derivados de etinila como moduladores de atividade de receptor de mglur5
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.

Legal Events

Date Code Title Description
FG Grant, registration